Annual report pursuant to Section 13 and 15(d)

Disclosure of Prior Period Financial Statement Error (Tables)

v3.20.2
Disclosure of Prior Period Financial Statement Error (Tables)
12 Months Ended
Jun. 30, 2020
Disclosure of Prior Period Financial Statement Error  
Summary of previously reported financial statements

Revised Consolidated Balance Sheets

Consolidated balance sheet

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2020

(In thousands)

    

As Reported

    

Adjustment

    

As Revised

Subscription receivable

 

$

 —

 

$

2,190

 

$

2,190

Total current assets

 

 

10,304

 

 

2,190

 

 

12,494

Total Assets

 

 

42,220

 

 

2,190

 

 

44,410

APIC

 

 

150,774

 

 

2,190

 

 

152,964

Total equity

 

 

3,957

 

 

2,190

 

 

6,147

Total liabilities and equity

 

 

42,220

 

 

2,190

 

 

44,410

 

Revised Consolidated Statement of Operations

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31, 2020

 

    

As Reported

    

Adjustment

    

As Revised

Loss per common share attributable to iBio, Inc. stockholders – basic and diluted

 

$

(0.06)

 

0.00

 

(0.06)

Weighted-average common shares outstanding – basic and diluted (000’s)

 

 

79,719

 

290

 

80,009

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

March 31, 2020

Loss per common share attributable to iBio, Inc. stockholders – basic and diluted

 

$

(0.74)

 

0.00

 

(0.74)

Weighted-average common shares outstanding – basic and diluted (000’s)

 

 

47,018

 

96

 

47,114